Table 3:

Pooled estimates of the effect of telemedicine on outcomes

OutcomeTime point, moNo. of trials and within-trial subgroups (no. of participants*)I2 statistic, %Pooled estimate (95% CI)
Mortality≤ 311 (1361)0RD,%: 0.2 (−0.6 to 0.9)
4–1242 (7197)0RD,%: −0.2 (−0.6 to 0.2)
> 124 (2376)0RD,%: −0.3 (−1.6 to 1.0)
HbA1C
HbA1C level, %≤ 339 (3165)75MD, %: −0.57 (−0.74 to −0.40)
4–1287 (15 524)69MD, %: −0.28 (−0.37 to −0.20)
> 125 (1896)58MD, %: −0.26 (−0.46 to −0.06)
HbA1C < 6.4% or < 6.5%4–121 (248)RR: 1.79 (0.98 to 3.27)
> 121 (80)RR: 2.33 (0.997 to 5.46)
HbA1C < 7%, ≤ 7% or ≤ 7.5%≤ 37 (1016)91RR: 2.30 (1.21 to 4.38)
4–1211 (1615)73RR: 1.46 (1.03 to 2.08)
HbA1C < 8% or ≤ 8%≤ 31 (137)RR: 2.28 (1.42 to 3.67)
4–123 (602)72RR: 1.20 (0.90 to 1.61)
HbA1C < 9%≤ 31 (137)RR: 1.31 (1.07 to 1.60)
4–121 (137)RR: 1.26 (1.04 to 1.52)
SF-36 (0–100)
Mental component summary≤ 32 (295)0MD: −1.06 (−3.19 to 1.07)
4–124 (784)63MD: 0.47 (−1.89 to 2.84)
Physical component summary≤ 32 (295)42MD: 0.92 (−1.97 to 3.81)
4–124 (784)0MD: 0.08 (−1.16 to 1.32)
Bodily pain≤ 32 (309)86MD: 5.46 (−8.64 to 19.56)
4–126 (1166)19MD: 0.44 (−2.19 to 3.07)
General health≤ 32 (306)0MD: 0.97 (−1.42 to 3.37)
4–126 (1163)58MD: 1.12 (−2.07 to 4.32)
Health transition4–121 (117)MD: 3.00 (−6.00 to 12.00)
Mental health≤ 32 (308)0MD: −1.09 (−3.19 to 1.01)
4–127 (1285)62MD: 2.31 (−0.24 to 4.86)
Physical functioning≤ 32 (311)30MD: −3.98 (−7.34 to −0.62)
4–127 (1288)58MD: 1.06 (−1.52 to 3.64)
Role emotional≤ 32 (304)0MD: −1.00 (−3.50 to 1.51)
4–126 (1161)80MD: 2.89 (−4.96 to 10.74)
Role physical≤ 32 (307)0MD: 0.30 (−2.38 to 2.97)
4–126 (1164)62MD: 2.20 (−3.62 to 8.02)
Social functioning≤ 32 (311)0MD: −2.22 (−4.34 to −0.10)
4–126 (1168)59MD: −0.27 (−3.78 to 3.24)
Vitality≤ 32 (310)0MD: 0.50 (−1.98 to 2.98)
4–126 (1167)69MD: 1.57 (−2.26 to 5.40)
SF-12 (0–100)4–121 (35)MD: −1.00 (−2.33 to 0.33)
Mental component summary4–123 (549)0MD: 0.51 (−1.26 to 2.29)
> 121 (204)MD: 2.37 (−2.15 to 6.89)
Physical component summary4–123 (549)7MD: −0.05 (−2.46 to 2.35)
> 121 (204)MD: 0.35 (−5.66 to 6.36)
Diabetes Quality of Life (1–5)≤ 31 (98)MD: −0.19 (−0.52 to 0.14)
4–126 (184)0MD: −0.003 (−0.10 to 0.09)
Diabetes-related worry≤ 32 (166)36MD: 0.03 (−0.25 to 0.32)
4–124 (302)67MD: 0.08 (−0.17 to 0.34)
Impact of diabetes≤ 32 (166)59MD: −0.01 (−0.31 to 0.28)
4–124 (302)60MD: 0.02 (−0.17 to 0.21)
Satisfaction with life≤ 31 (68)MD: 0.24 (−0.05 to 0.53)
4–124 (222)47MD: 0.16 (−0.02 to 0.33)
Social/vocational worry≤ 31 (98)MD: −0.12 (−0.33 to 0.09)
4–123 (249)54MD: −0.05 (−0.29 to 0.20)
Diabetes Distress Scale (1–6)4–126 (777)0MD: −0.01 (−0.17 to 0.15)
EQ-5D (0–1)4–122 (743)0MD: −0.01 (−0.01 to −0.01)
PAID (0–100)4–122 (363)0MD: 2.86 (1.74 to 3.97)
Hypoglycemia (patient-years)≤ 33 (46)0RR: 0.94 (0.80 to 1.12)
4–125 (848)93RR: 0.86 (0.66 to 1.12)
Severe hypoglycemia (patient-years)4–12§4 (427)92RR: 0.59 (0.17 to 2.05)
Hypoglycemia (% of patients affected)≤ 35 (462)63RD, %: 0.0 (−5.5 to 5.5)
4–124 (282)47RD, %: 3.1 (−7.9 to 14.2)
Severe hypoglycemia≤ 31 (92)RD, %: 0.0 (−4.2 to 4.2)
4–1210 (1259)0RD, %: −0.1 (−1.0 to 0.8)
  • Note: CI = confidence interval, EQ-5D = European Quality of Life survey with 5 dimensions, HbA1C = glycated hemoglobin, MD = difference in means, PAID = Problem Areas in Diabetes, RD = difference in risk, RR = risk ratio or rate ratio, SF-12 = 12-item Short Form Health Survey, SF-36 = 36-item Short Form Health Survey, – = not applicable.

  • * We used effective sample sizes in cluster trials and patient-years for rate ratios.

  • Large values indicate a better quality of life.

  • Small values indicate a better quality of life.

  • § No data available for time point ≤ 3 mo.